M. Thompson

Validation of a 4D-PET maximum intensity projection for delineation of an internal target volume.

Tomas Kron, David Binns, Shankar Siva, 2013, International journal of radiation oncology, biology, physics.

Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study

M. Jefford, I. Campbell, R. Hicks, 2021, Cancer Chemotherapy and Pharmacology.

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

Jennifer H. Martin, M. Jefford, I. Campbell, 2021, European Journal of Clinical Pharmacology.

In vivo tracking for cell therapies.

R. Hicks, H. Prince, M. Thompson, 2005, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

R. Hicks, M. Michael, M. Hofman, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma

M. Loudovaris, L. Mileshkin, R. Hicks, 2008, Journal of immunotherapy.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

John R Zalcberg, Michael Michael, Mick Thompson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma

L. Mileshkin, H. Prince, P. Eu, 2006, Cancer Immunology, Immunotherapy.

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

M. Jefford, R. Hicks, C. Karapetis, 2021, European Journal of Clinical Pharmacology.

Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors

R. Hicks, P. Lobachevsky, P. Jackson, 2015, The Journal of Nuclear Medicine.

68 Ga-EDTA PET / CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification : Comparison to Conventional 51 Cr-EDTA

S. Siva, R. Hicks, M. Hofman, 2015 .

Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors

R. Hicks, P. Lobachevsky, P. Jackson, 2015, The Journal of Nuclear Medicine.

In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma

M. Loudovaris, L. Mileshkin, R. Hicks, 2008, Journal of immunotherapy.

The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).

S. Bates, A. Scott, J. Zalcberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.